KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abbott Laboratories (ABT) Other Non Operating Income (2016 - 2025)

Abbott Laboratories' Other Non Operating Income history spans 17 years, with the latest figure at $134.0 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 12.99% year-over-year to $134.0 million; the TTM value through Dec 2025 reached $548.0 million, up 45.74%, while the annual FY2025 figure was $548.0 million, 45.74% up from the prior year.
  • Other Non Operating Income for Q4 2025 was $134.0 million at Abbott Laboratories, down from $150.0 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $496.0 million in Q4 2023 and bottomed at -$304.0 million in Q3 2023.
  • The 5-year median for Other Non Operating Income is $82.0 million (2022), against an average of $73.7 million.
  • The largest annual shift saw Other Non Operating Income tumbled 1500.0% in 2023 before it surged 2670.0% in 2025.
  • A 5-year view of Other Non Operating Income shows it stood at -$136.0 million in 2021, then dropped by 5.15% to -$143.0 million in 2022, then surged by 446.85% to $496.0 million in 2023, then tumbled by 68.95% to $154.0 million in 2024, then decreased by 12.99% to $134.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABT's Other Non Operating Income are $134.0 million (Q4 2025), $150.0 million (Q3 2025), and $257.0 million (Q2 2025).